EU Approves Merck’s Keytruda Plus Chemotherapy To Treat Triple-Negative Breast Cancer

Easy to ride bikes

I am a first-time bike buyer from Kerala who is in the market for a 100-110cc bike. I am 5’10” tall and travel around 10km in heavy traffic on a daily basis, with an occasional long trip. I want a bike which is around ₹60,000, low maintenance, easy-to-use and fuel-efficient without compromising on performance. An electric start is desired. Looks and ancillary electronic additions are not important. Kindly advise.

Ajay David, via email

There are many 110cc options available, but our favourite is the TVS Radeon. It is a comfortable and practical motorcycle that has good fuel efficiency. Most of all though, the Radeon is fun to ride and has an involving exhaust note. We recommend you spend the extra bucks for a disc brake model.

I use a 2017 model Honda City petrol VX (4th gen) and intend to upsize the stock 185/ 55 R16 tyres to at least 195. Will the upsizing impact suspension, steering and mileage? I am looking to reduce road noise and increase comfort. Request your suggestions for a tyre brand and model accordingly.

Neville Mistry, via email

You can upgrade the City’s tyres to 195/55-R-16. They are easily available from most Indian and foreign manufacturers. You can consider the Pirelli P7 Cinturato, Bridgestones and Goodyears for the Honda City.

Hormazd Sorabjee is the editor of Autocar India. Mail your feedback and queries to [email protected]thehindu.co.in

Person dies after falling from moving car in Kawakawa Bay

A person’s died after falling from a moving vehicle in south-east Auckland.

It happened on Clevedon-Kawakawa Road in Kawakawa Bay, just before 7pm last night.

Police say the person died at the scene.

They say enquiries are underway to determine the circumstances.

The road was initially closed but has since re-opened.

Vodafone Idea opts for pause on spectrum dues

Moratorium to end in September 2025

Vodafone Idea on Wednesday said its board has approved availing the four-year spectrum payment moratorium being offered by the government as part of its relief package for the telecom sector.

The other options offered in the Telecom Department’s notification will be considered by the board of directors within the stipulated timeframe, it said in a regulatory filing.

“We wish to inform you that the board of directors of the company has approved the exercise of the option of deferment of the company’s spectrum auction instalments for a period of 4 years (October 2021 to September 2025) in accordance with the notification dated 14 October 2021 issued by the Department of Telecommunications (DoT) to the company,” it said.

The government last week wrote to telcos asking them to convey by October 29 if they would be opting for the moratorium. Bharti Airtel chairman Sunil Mittal had, last month, said the company will opt for the payment moratorium.

Twenty-Year Bond Auction Attracts Below Average Demand

The Treasury Department on Wednesday announced the results of this month’s auction of $24 billion worth of twenty-year bonds, with the sale attracting below average demand.

The twenty-year bond auction drew a high yield of 2.100 percent and a bid-to-cover ratio of 2.25.

Last month, the Treasury also sold $24 billion worth of twenty-year bonds, drawing a high yield of 1.795 percent and a bid-to-cover ratio of 2.36.

The bid-to-cover ratio is a measure of demand that indicates the amount of bids for each dollar worth of securities being sold.

The ten previous twenty-year bond auctions had an average bid-to-cover ratio of 2.35.

Opinion | How I Became a Sick Person


By Ross Douthat

Opinion Columnist

Ally Financial Q3 Results Top Estimates; To Buy Fair Square Financial For $750 Mln Cash -Quick Facts

Ally Financial Inc. (ALLY), a bank holding company, reported Thursday that third-quarter net income attributable to shareholders increased to $683 million or $1.89 per share from $476 million or $1.26 per share in the year-ago quarter.

Excluding items, adjusted earnings for the quarter were $2.16 per share, compared to $1.25 per share in the prior-year quarter.

On average, 18 analysts polled by Thomson Reuters expected the company to report earnings of $1.95 per share for the quarter. Analysts’ estimates typically exclude special items.

Total net revenue for the quarter grew 18 percent to $1.99 billion from $1.68 billion in the year-ago quarter. Adjusted total net revenue increased 26 percent from last year to $2.11 billion. Analysts expected revenue of $2.02 billion for the quarter.

Ally Financial said its board of directors approved a $0.25 per share common dividend for the fourth quarter of 2021.

Additionally, Ally has entered into a definitive agreement to acquire Fair Square Financial for $750 million in an all-cash transaction. The transaction, unanimously approved by Ally’s board of directors, is expected to close by the end of the first quarter 2022. Ally expects thetransaction to further enhance profitability and risk-adjusted returns.

EU Approves Merck’s Keytruda Plus Chemotherapy To Treat Triple-Negative Breast Cancer

The European Commission has approved Merck & Co. Inc.’s (MRK) anti-PD-1 therapy, Keytruda, in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer in adults whose tumors express PD-L1 and who have not received prior chemotherapy for metastatic disease, the company said in a statement on Friday.

The approval allows marketing of the combination with Keytruda in all 27 European Union member states plus Iceland, Lichtenstein, Norway and Northern Ireland.

Triple-negative breast cancer is an aggressive type of breast cancer. It represents Keytruda’s first approval in Europe in a breast cancer setting.

The approval was based on final analysis from the Phase 3 KEYNOTE-355 trial, in which Keytruda in combination with chemotherapy significantly improved overall survival, reducing the risk of death by 27%, and progression-free survival, reducing the risk of disease progression or death by 34% compared to chemotherapy alone in these patients.